Nucleotide Enhancement Agents for Stable RNA Delivery and Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Efficient delivery of genetic materials such as RNA to cells in vivo is hindered by the need for specific targeting and protection from the extracellular environment, particularly serum proteins, with existing conjugates failing to achieve clinically relevant knockdown activities and specificity due to poor pharmacokinetic and ADME profiles, lack of tissue accumulation, and inefficient cellular uptake.
Innovation Solution
The development of Nucleotide-Based Enhancement Agents, comprising specific nucleotide structures and linkers, to improve targeted delivery efficiency by enhancing binding affinity with serum proteins, increasing nuclease resistance, and facilitating intracellular trafficking and endosomal escape.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional conjugates are used for RNA delivery, then targeting capability is provided, but delivery efficiency and cellular uptake remain insufficient
Solution Approach 1:
The patent applies composite materials by combining GalNAc ligands with specific nucleotide sequences (enhancement agents) to create a hybrid conjugate structure. This composite approach integrates the targeting capability of GalNAc with the cellular uptake enhancement of specific nucleotide sequences, achieving synergistic effects that overcome the limitations of conventional single-component conjugates.
Solution Approach 2:
The patent utilizes parameter changes by optimizing the nucleotide sequence composition, length, and structural characteristics of the enhancement agents. By systematically varying these parameters, the invention identifies sequences that maximize cellular uptake efficiency while maintaining stable conjugation with GalNAc ligands, thereby resolving the contradiction between delivery efficiency and cellular uptake.
2Reliability
If nucleic acid is delivered to cells, then therapeutic effect is achieved, but stability in cellular environment deteriorates
Solution Approach 1:
The patent employs nucleotide-based enhancement agents as intermediaries that mediate between the GalNAc ligand and the therapeutic nucleic acid. These enhancement agents protect the nucleic acid from cellular degradation while facilitating its delivery, acting as a protective buffer that maintains nucleic acid stability in the harsh cellular environment without compromising therapeutic efficacy.
Solution Approach 2:
The patent applies parameter changes by modifying the nucleotide sequence parameters of the enhancement agents to optimize their protective function. Specific sequence compositions and structural parameters are selected to maximize nuclease resistance and cellular stability, thereby maintaining nucleic acid integrity throughout the delivery process and intracellular journey.
3Measurement precision
If targeting moiety is conjugated to nucleic acid, then specific targeting is achieved, but pharmacokinetic and ADME profiles deteriorate
Solution Approach 1:
The patent applies segmentation by dividing the conjugate into distinct functional modules: the GalNAc targeting ligand, the nucleotide-based enhancement agent, and the therapeutic nucleic acid. This modular segmentation allows each component to perform its specific function optimally while minimizing interference with pharmacokinetic properties. The enhancement agent segment specifically addresses ADME concerns by improving solubility and stability without compromising targeting specificity.
4Device complexity
If conventional delivery methods are used, then simplicity is maintained, but tissue accumulation and cellular activity are insufficient
Solution Approach 1:
The patent employs self-service principles by designing enhancement agents with intrinsic properties that automatically enhance delivery performance. The specific nucleotide sequences self-assemble and interact with cellular components to facilitate uptake and accumulation without requiring additional complex delivery mechanisms. This self-enhancing capability achieves improved tissue accumulation while maintaining relative structural simplicity.
Data Source
AI summary
The present disclosure provides a Nucleotide-Based Enhancement Agent being a compound or a pharmaceutically acceptable salt thereof, comprising from 2 to 30 nucleotides, wherein each nucleotide independently is of Formula (I) or (II):pharmaceutically acceptable salts thereof, and related conjugates. The present disclosure also relates to uses of the Nucleotide-Based Enhancement Agents and conjugates, e.g., in delivering nucleic acid and/or treating or preventing diseases.